The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

The FDA is phasing out an animal testing requirement for monoclonal antibody therapies in favor of testing drugs on ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect ...

This is a groundbreaking step toward advancing public health by using more effective and human-relevant methods instead of ...

Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease pathogenesis. In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled ...

The Biden administration's FDA "seemed to be inert" on the issue, and even "obstructionist," after Congress removed mandatory animal testing, longtime group leader says. Bill to ban research funding ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T ...

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...